Skip to content
Review Open access

Lung cancer metabolism: a dynamic and adaptive network

Oct 2026 · Cellular and Molecular Life Sciences · Vol 83 · 0 citations · 132 references
Medicine

TL;DR

This review presents lung cancer metabolism as an integrated and adaptable system rather than a collection of isolated pathways, and identifies metabolic dependencies that may be leveraged for therapeutic intervention.

Abstract

Lung cancer remains the leading cause of cancer-related mortality worldwide. Although substantial progress has been made in defining the genetic, epigenetic, and molecular drivers of this heterogeneous disease, metabolic reprogramming has only recently emerged as a major determinant of tumour progression and therapeutic response. Cumulative evidence demonstrates that rather than relying on a single nutrient source or pathway, cancer cells integrate glucose and glutamine, fatty acid and one-carbon metabolism, as well as nucleotide biosynthesis, and redox-supporting circuits in a highly context-dependent manner. These programs vary across histological and molecular subtypes, reflecting the influence of lineage identity and oncogenic state on metabolic organisation. In both non-small cell lung cancer and small cell lung cancer, subtype-specific constraints shape distinct metabolic states, yet a common feature is the ability to rapidly shift between alternative nutrients and biosynthetic routes. This adaptability supports continued growth under nutrient limitation, maintains redox homeostasis, and contributes to resistance against conventional and targeted therapies. By summarising current mechanistic evidence, this review presents lung cancer metabolism as an integrated and adaptable system rather than a collection of isolated pathways, and identifies metabolic dependencies that may be leveraged for therapeutic intervention.

Read PDF

Similar papers

Review Open access Oct 2026

Genes, fuel, and fate in lung cancer

Abstract Cellular plasticity is a central feature of malignant progression, allowing tumour cells to change identity during tumour evolution, therapeutic adaptation, and metastatic dissemination. This issue is especially acute in lung cancer, where the respiratory epithelium is intrinsically permissive to cell-state ch...

Julia S. Scott, C. Lutz, S. Preković · 0 citations
Review Oct 2026

Metabolic reprogramming and plasticity in breast Cancer: Mechanisms driving tumor progression, metastasis, and therapeutic resistance.

Breast cancer remains the most frequently diagnosed malignancy and a leading cause of cancer-related mortality among women worldwide. Despite substantial advances in endocrine therapy, human epidermal growth factor receptor 2 (HER2)-targeted therapy, chemotherapy, and immunotherapy, therapeutic resistance and metastati...

Jie Yuan, Hua Zhang, Jun Huang et al. · 0 citations
Review Open access Oct 2026

Adaptive Rewiring of Nucleotide Metabolism in Therapeutic Resistance.

Therapeutic resistance remains a major barrier to durable cancer control and is increasingly recognized as a dynamic process shaped not only by genetic evolution but also by metabolic adaptation. Nucleotide metabolism is uniquely positioned at this interface, supporting DNA and RNA synthesis while also regulating signa...

B. Dayanc, Gan-Fei Xu, Xiao-Shu Zhou et al. · 0 citations
Review Open access Sep 2026

Cancer Metabolism: Recent Advances in Biochemical Mechanisms and Targeted Therapeutic Strategies

Background: Cancer is characterized not only by genetic and epigenetic abnormalities but also by profound alterations in cellular metabolism. Metabolic reprogramming enables malignant cells to meet the increased requirements for energy production, biosynthesis, redox regulation, proliferation, invasion, and adaptation...

Arshiya Fatima, Mohammed Abdul Muqeeth, K. Maanasa et al. · 0 citations
Review Open access Sep 2026

Mitochondrial metabolic-transcriptional axis drives adaptive drug tolerance across major lung cancer subtypes

Drug resistance remains the first and most significant barrier to long-term curative benefits in lung cancer patients. Traditional resistance mechanisms focused on oncogenic driver mutations are inadequate to explain reversible tumor phenotypic plasticity under therapeutic stress. Increasing evidence has placed mitocho...

Rui-Xuan Liu, Xin-Yao Wang, Ze-Tong Li et al. · 0 citations
Review Open access Oct 2026

Metabolic processes and microenvironmental regulation in leukemia.

ABSTRACT Leukemia, a heterogeneous group of hematologic malignancies, continues to present significant therapeutic challenges owing to persistent issues, such as relapse, drug resistance, and treatment-related toxicity. While traditional research has primarily focused on genetic drivers, there is increasing recognition...

Bin-He Chang, Yong Wang, Zi-Juan Li et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.